High-dose treatment with autologous stem cell support in a Norwegian region;Høydosebehandling med stamcellestøtte i Midt-Norge

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 19, 2004, Pages 2498-2500

  Hammerstrøm, Jens ^a   Aasland, Irene Line ^a   Telhaug, Ragnar ^a   Moen, Torolf ^a   Lødemel, Bottolf ^b   Sørum, Yngve ^b   Brudevold, Robert ^b   Herlofsen, Oluf ^b   Sørbø, Jon Hjalmar ^c   Almvik, Turid ^a   Lamvik, Jon ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b Volda Sjukehus ^*  (Norway)

^c Levanger Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; DRUG EFFICACY; DRUG MEGADOSE; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; TESTIS CANCER; ADULT; AGED; COMPARATIVE STUDY; FEMALE; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; NORWAY; RETROSPECTIVE STUDY; STANDARD; TESTIS TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; NORWAY; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 5444274765     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Høydosebehandling med perifer stamcellestøtte ved maligne lidelser. Helsedirektoratets utredningsserie I-95. Oslo: Statens helsetilsyn, 1995.
2. Husebekk A, Kolstad A, Dahl IMS et al. Regionalisert høydose cellegiftbehandling med autolog stamcellestøtte. Tidsskr Nor Lægeforen 1998; 118: 2777-80.
3. Abrahamsen JF, Kristoffersen EK, Hervig T et al. Høydosebehandling med autolog stamcellestøtte hos kreftpasienter, Tidsskr Nor Lægeforen 2000; 120: 1523-8.
4. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed mutiple myeloma: a population based study. Blood 2000; 95: 7-11.
5. Wisløff F, Tangen J-M, Brinch L et al. Høydosebehandling med autolog stamcellestøtte - endelig et fremskritt ved myelomatose. Tidsskr Nor Lægeforen 2001; 121: 2402-6.
6. Aurlien E, Holte H, Kvaloy S et al. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pretreated relapsed lymphoma patients. Eur J Haematol Suppl 2001; 14-20,
7. Scmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-71.
8. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 2000; 356: 1384-91.
9. Swenoteca III og IV. Behandling av non-seminomatös testikelcancer. www.ocsyd.lu.se/vardprog/swenoteca3o4.pdf (9.1.2004).
10. Shipp MA, Abeloff MD, Antman K et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive Non Hodgkins's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-9.
11. Norsk Lymfomgruppe. Norsk handlingsprogram for diagnostikk og behandling av maligne lymfomer. www.kreft.no (9.1.2004).
12. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
13. Sweetenham JW, Santini G, Qian W et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Bone Marrow Transplantation and the United Kingdom Lymphoma group. J Clin Oncol 2001; 19: 2927-36.
14. Philip T, Guglielmi C, Hagenbeck A et al. Autoogous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
15. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
16. Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
17. Bjorkstrand B. European group for blood and bone marrow transplantation registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-25.